Kim Anna Reiss, MD, University of Pennsylvania, Philadelphia, PA, describes the rationale and trial design of the Phase II APOLLO trial (NCT04858334), which assessed olaparib following completion of surgery and chemotherapy in patients with pancreatic cancer and a BRCA1, BRCA2 or PALB2 mutation. The trial is based on the Phase III POLO (NCT02184195) and OLYMPIA (NCT02032823) trials of maintenance Olaparib in BRCA-mutated pancreatic cancer and breast cancer respectively. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.